Catheter Precision (VTAK) to Release Earnings on Friday

Catheter Precision (NYSEAMERICAN:VTAKGet Free Report) will likely be releasing its results before the market opens on Friday, March 27th. Analysts expect Catheter Precision to post earnings of ($20.90) per share and revenue of $1.70 million for the quarter.

Catheter Precision Stock Performance

VTAK stock opened at $1.31 on Friday. The stock has a 50-day moving average price of $1.76 and a two-hundred day moving average price of $2.12. Catheter Precision has a 1 year low of $1.14 and a 1 year high of $15.68. The company has a current ratio of 0.46, a quick ratio of 0.46 and a debt-to-equity ratio of 0.20.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAKFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent filing with the Securities and Exchange Commission. 20.34% of the stock is currently owned by institutional investors and hedge funds.

About Catheter Precision

(Get Free Report)

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.

Featured Stories

Earnings History for Catheter Precision (NYSEAMERICAN:VTAK)

Receive News & Ratings for Catheter Precision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catheter Precision and related companies with MarketBeat.com's FREE daily email newsletter.